1-(1-hydroxy-2-methylpropan-2-yl)-3-[3-[3-(oxan-4-yloxy)-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propyl]urea

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-hydroxy-2-methylpropan-2-yl)-3-[3-[3-(oxan-4-yloxy)-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propyl]urea
• 化学式: C₃₂H₅₀N₄O₁₁
• 分子量: 666.8
• InChiKey: WEXHNAZGAWEZDH-JGALVPIPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  47
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  217
• 氢给体数：
  8
• 氢受体数：
  12

文献信息

• PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF
  申请人：Fushimi Nobuhiko

  公开号：US20090203633A1

  公开（公告）日：2009-08-13

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C 1-6 alkyl group etc.; R 2 represents H, a halogen atom, OH, an optionally substituted C 1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C 1-6 alkylene group etc.; Z represents —R B , —COR C etc. in which R B represents an optionally substituted C 1-6 alkyl group etc.; and R C represents an optionally substituted C 1-6 alkyl group etc.; R 4 represents H, an optionally substituted C 1-6 alkyl group etc.; and R 3 , R 5 and R 6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由以下通式表示的吡唑衍生物：其中R1代表H，可选取代的C1-6烷基等；Q和T中的一个代表由以下通式表示的基团：或者由以下通式表示的基团：而另一个代表可选取代的C1-6烷基等；R2代表H，卤素原子，OH，可选取代的C1-6烷基等；X代表单键，O或S；Y代表可选取代的C1-6亚烷基等；Z代表-RB，-CORC等，其中RB代表可选取代的C1-6烷基等；而RC代表可选取代的C1-6烷基等；R4代表H，可选取代的C1-6烷基等；而R3、R5和R6代表H，卤素原子等，其在人类SGLT1中表现出优异的抑制活性，可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖耐量受损、空腹血糖异常、糖尿病并发症或肥胖症，以及与血液半乳糖水平升高相关的疾病，如半乳糖血症的药物，并且包括这些衍生物的制药组合物、制药用途和其生产的中间体。
• US7635684B2
  申请人：——

  公开号：US7635684B2

  公开（公告）日：2009-12-22
• US8324176B2
  申请人：——

  公开号：US8324176B2

  公开（公告）日：2012-12-04